Lumida
/AZN
⌘K
AstraZeneca PLC

AstraZeneca PLC

AZN
$168.90USD↓-0.23%-0.39 today

MARKET CAP

144.9B

P/E (TTM)

18.3x

FWD P/E

15.1x

DAY RANGE

$167 – $170

52W RANGE

$137
$213

AI Summary

Stalk
TrimMedium

AZN remains in a Stage 4 decline with a bearish medium-term bias after the support failure in mid-July. Price sits below the 9 and 20 EMAs and has been unable to reclaim these levels on the recent oversold bounce, suggesting sell-side control. The long-term uptrend is intact above the rising 200 DMA, capping risk, but rallies need to be watched for rejections at falling EMAs to maintain the bearish stance. A decisive reclaim and close above the EMAs would warrant a reassessment.

  • ↑Q1 2025 revenue rose 10% YoY to $11.7 B; core EPS up 21% to $2.49.
  • ↑Oncology sales jumped 16% YoY to $6.8 B, led by strong Infinzi uptake.
  • ↓Wainua trial failure reduces near-term revenue visibility.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

AstraZeneca PLC (NASDAQ: AZN) is a leading biopharmaceutical company that develops innovative medicines across various therapeutic areas, including oncology, respiratory diseases, cardiovascular, and metabolic diseases. It holds a dominant position in the oncology segment, characterized by multiple blockbuster drugs and a robust FDA-approved pipeline. AstraZeneca is a key player in the pharmaceutical landscape and is poised to benefit from emerging trends in healthcare, especially with its extensive investment in innovation and research, aiming to reach an ambitious $80 billion revenue target by 2030.

Bull says

  • ↑Q1 2025 revenue rose 10% YoY to $11.7 B; core EPS up 21% to $2.49.
  • ↑Oncology sales jumped 16% YoY to $6.8 B, led by strong Infinzi uptake.
  • ↑Deep pipeline with 100+ Phase III trials aimed at $10B+ peak revenues.
  • ↑50% planned CapEx increase to expand manufacturing and support launches.
  • ↑High earnings and dividend yields underpin shareholder returns and profitability.
  • ↑Diversified portfolio offsets setbacks; management targets 30% share gain by 2030.

Bear says

  • ↓Wainua trial failure reduces near-term revenue visibility.
  • ↓Farsiga faces looming generic entries and pricing‐reform pressure.
  • ↓Rising net debt elevates leverage risk amid higher rates.
  • ↓High short interest signals market skepticism on growth prospects.
  • ↓Surging R&D spend may strain liquidity if pipeline misses.
  • ↓Analyst revisions are negative, reflecting waning confidence in forecasts.

Investment themes with AZN

Weight Loss↓ -0.82%

Products and services targeting weight management

LLY · NVO · PFE
Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • Total revenue grew 8% in the quarter, supported by robust demand for innovative medicines.
  • We saw strong growth in operating profit, which increased 12%, reflecting our ongoing focus on operating leverage.
  • In the past weeks, we announced results from four positive phase 3 programs, including two NMEs, Tozorakimab and Epsymfotate Alpha.

Bear points

  • Solaris revenues continued to decline due to successful conversion to Ultramiris, as well as biosimilar pressure.
  • the discontinuation of ultramiris in CSA-AKI high-risk patients with kidney ischemia due to lack of consistent efficacy across CKD severities.
  • Overall, biopharmaceuticals total revenue declined by 2% to $5.8 billion.
Read full transcript analysis ›